Today: 4 July 2026
Browse Category

NASDAQ:RVPH 24 October 2025 - 9 March 2026

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Cupertino, Calif., March 9, 2026, 06:42 PDT Reviva Pharmaceuticals Holdings implemented its 1-for-20 reverse stock split just after midnight Eastern Time on Monday, combining 20 shares into a single share. The move is aimed at boosting the company’s share price to maintain its Nasdaq listing. Reviva said the stock will start trading on a split-adjusted basis at the opening bell.
9 March 2026
·
Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for its lead schizophrenia candidate, brilaroxazine, before filing a New Drug Application. SEC+1 Shares were trading around $0.32 after the drop, reflecting how quickly biotech valuations can reprice when timelines and funding needs change—especially for micro-cap clinical-stage companies. StockAnalysis
24 December 2025
···
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals Holdings, Inc. is back on traders’ radar as a late‑stage CNS biotech preparing for a potential New Drug Application in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside targets. As of mid‑session on December 10, 2025, RVPH is trading around $0.69 per share, up roughly 10% on the day, implying a market capitalization of about $78–80 million.Simply Wall St That price sits near the low end of its 12‑month range of roughly $0.25 to $3.00, with the share price still down more than 70% over the past year despite a series of positive clinical and regulatory updates.MarketBeat+2Stocktwits+2
10 December 2025
··
Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

Reviva Pharma Rockets 28% on Schizophrenia Trial Win – Analysts Eye 1000% Upside

As of Oct 24, 2025, RVPH shares trade around $0.57 investing.com, after a volatile October run. The stock has surged ~28% on Oct 23 after a prior drop. Recent catalysts include completion of a 1-year Phase 3 trial showing robust, sustained efficacy revivapharma.com, and plans for an FDA meeting in Q4 2025 toward a 2026 NDA revivapharma.com. Reviva also raised capital via equity offerings to fund its CNS pipeline. Analysts remain extremely bullish – consensus is “Strong Buy” with an average 12‑month target around $6.25 investing.com investing.com. By comparison, MarketBeat reports a mean $4.86 target marketbeat.com. In the broader biotech space, industry news and deals are driving rallies. RVPH has been highly volatile in recent weeks. After trading near $0.30 in late September, it leapt to ~$0.84 by Oct 7 markets.financialcontent.com. The stock then pulled back into the low $0.40s before soaring again by Oct 23 to $0.5675 markets.financialcontent.com. In one day the shares gained +28.5% markets.financialcontent.com. A Benzinga report notes RVPH fell ~22.8% to $0.65 on Oct 8 benzinga.com – highlighting how quickly sentiment can swing. As of the Oct 24 session, RVPH is hovering around $0.57 investing.com. Over the past month, it has ranged from a low near
24 October 2025
···

Stock Market Today

  • Rolls-Royce Flags Defence Spending Tailwind, Bombardier Tie-Up and Board Changes
    July 3, 2026, 9:31 PM EDT. Rolls-Royce Holdings (LSE:RR.) is set to benefit from a boost in UK government defence spending, with focus on advanced warfare and propulsion tech. The company points to upside for its defence engines and support projects. Rolls-Royce struck a deal with Bombardier to step up aircraft engine monitoring. The board is bringing in new non-executive directors to strengthen governance. The stock is up 25.7% for the year, sitting 5.1% above analysts' targets and running 58.7% above estimated fair value, making valuation look stretched. Forecasts point to earnings dropping by 3.1% a year over the next three years, putting sustainability of recent gains in question. Investors are watching how defence contracts, the Bombardier partnership, and board moves will hit revenue, margins, and cash flow.
Go toTop